ES2162843T3 - Inhibidores de la proteina quinasa c. - Google Patents

Inhibidores de la proteina quinasa c.

Info

Publication number
ES2162843T3
ES2162843T3 ES94308947T ES94308947T ES2162843T3 ES 2162843 T3 ES2162843 T3 ES 2162843T3 ES 94308947 T ES94308947 T ES 94308947T ES 94308947 T ES94308947 T ES 94308947T ES 2162843 T3 ES2162843 T3 ES 2162843T3
Authority
ES
Spain
Prior art keywords
inhibitors
protein
quinasa
protein quinasa
macrociclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94308947T
Other languages
English (en)
Inventor
William Francis Heath Jr
Michael Robert Jirousek
John Hampton Mcdonald Iii
Christopher John Rito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2162843T3 publication Critical patent/ES2162843T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION PROPORCIONA NUEVOS DERIVADOS DEL MACROCICLO BISINDOLEMALEIMIDA CON LA FORMULA INDICADA. LA INVENCION ADEMAS FACILITA LA PREPARACION, FORMULACIONES FARMACEUTICAS Y LOS METODOS DE USO PARA INHIBIR LA QUINASA DE PROTEINA C EN MAMIFEROS.
ES94308947T 1993-12-07 1994-12-02 Inhibidores de la proteina quinasa c. Expired - Lifetime ES2162843T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US31697394A 1994-10-03 1994-10-03

Publications (1)

Publication Number Publication Date
ES2162843T3 true ES2162843T3 (es) 2002-01-16

Family

ID=26859318

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94308947T Expired - Lifetime ES2162843T3 (es) 1993-12-07 1994-12-02 Inhibidores de la proteina quinasa c.

Country Status (30)

Country Link
US (1) US5698578A (es)
EP (1) EP0657458B1 (es)
JP (2) JP3581731B2 (es)
KR (1) KR100340159B1 (es)
CN (2) CN1050844C (es)
AT (1) ATE204579T1 (es)
AU (1) AU687909B2 (es)
BR (1) BR9404831A (es)
CA (1) CA2137203C (es)
CO (1) CO4340622A1 (es)
CY (1) CY2413B1 (es)
CZ (1) CZ291950B6 (es)
DE (1) DE69428025T2 (es)
DK (1) DK0657458T3 (es)
ES (1) ES2162843T3 (es)
FI (3) FI108138B (es)
GR (1) GR3037087T3 (es)
HU (1) HU219709B (es)
IL (1) IL111850A (es)
MY (1) MY125587A (es)
NO (1) NO308798B1 (es)
NZ (1) NZ270048A (es)
PE (1) PE49195A1 (es)
PL (1) PL182124B1 (es)
PT (1) PT657458E (es)
RU (1) RU2147304C1 (es)
SG (1) SG63570A1 (es)
TW (1) TW425397B (es)
UA (1) UA44690C2 (es)
YU (1) YU49200B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104412A3 (es) * 2010-02-25 2011-11-17 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
PL184728B1 (pl) * 1995-11-20 2002-12-31 Lilly Co Eli Nowe pochodne bisindolilomaleimidu z mostkiem N,N'i środek farmaceutyczny
SI0776895T1 (en) * 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
US5919946A (en) * 1996-03-20 1999-07-06 Eli Lilly And Company Synthesis of indolylmaleimides
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
EA001450B1 (ru) * 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
CZ350098A3 (cs) 1996-05-01 1999-11-17 Eli Lilly And Company Způsob léčení neoplasie
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
CN1231607A (zh) * 1996-08-30 1999-10-13 伊莱利利公司 利用pkg抑制剂来生产治疗与hiv感染相关的中枢神经系统疾病的药物的用途
WO1998008510A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
WO1999038828A1 (en) * 1998-01-30 1999-08-05 Daiso Co., Ltd. Process for producing butanetriol derivative
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
ATE251624T1 (de) * 1998-03-13 2003-10-15 Univ British Columbia Granulatimide-derivate zur behandlung von krebs
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
ATE301661T1 (de) * 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
ES2280596T3 (es) * 2001-12-29 2007-09-16 Novo Nordisk A/S Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
US7691861B2 (en) * 2004-01-19 2010-04-06 Novartis Ag Indolymaleimide derivatives
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
CA2645289A1 (en) * 2006-03-10 2007-09-20 Janssen Pharmaceutica, N.V. Pyridine-containing macroheterocylic compounds as kinase inhibitors
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
RU2441000C2 (ru) * 2009-11-27 2012-01-27 Общество с ограниченной ответственностью "Молекулярные Технологии" 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
KR101461767B1 (ko) 2010-03-30 2014-11-13 노파르티스 아게 만성 활성 ｂ-세포-수용체 신호전달이 있는 ｂ-세포 림프종의 치료를 위한 ｐｋｃ 억제제
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
WO2014085381A1 (en) 2012-11-29 2014-06-05 Novartis Ag Pharmaceutical combinations
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
ES2933350T3 (es) 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
WO2016003450A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru) 2015-07-06 2022-01-26 Тёрнинг Поинт Терапьютикс, Инк. Полиморфная форма диарильного макроцикла
PT3733187T (pt) * 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
LT3728271T (lt) 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof
JP2026505008A (ja) * 2023-01-27 2026-02-10 メリセル，インコーポレイテッド 肥満および脂肪細胞肥大化に関連する疾患の治療のための方法および組成物
EP4698538A1 (en) * 2023-04-21 2026-02-25 4M Therapeutics Inc. Polymorphs of n-desmethyl ruboxistaurin and salts thereof
CN117362170A (zh) * 2023-10-13 2024-01-09 四川美大康华康药业有限公司 一种索马鲁肽中间体的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
FR2614022B1 (fr) * 1987-04-15 1989-12-01 Roussel Uclaf Nouveaux derives 17-aza de 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et ces compositions les renfermant
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
CA2108146A1 (en) * 1991-04-11 1992-10-12 Stuart W. Mccombie Anti-tumor and anti-psoriatic agents
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011104412A3 (es) * 2010-02-25 2011-11-17 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer
ES2385157A1 (es) * 2010-02-25 2012-07-19 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.

Also Published As

Publication number Publication date
CA2137203A1 (en) 1995-06-08
PL182124B1 (pl) 2001-11-30
US5698578A (en) 1997-12-16
HU219709B (hu) 2001-06-28
HK1013827A1 (en) 1999-09-10
NO944643L (no) 1995-06-08
FI20011109L (fi) 2001-05-28
EP0657458A1 (en) 1995-06-14
JP2004269543A (ja) 2004-09-30
KR100340159B1 (ko) 2002-11-23
RU94042922A (ru) 1996-12-27
AU687909B2 (en) 1998-03-05
FI108138B (fi) 2001-11-30
CZ291950B6 (cs) 2003-06-18
EP0657458B1 (en) 2001-08-22
CY2413B1 (en) 2004-11-12
CN1055089C (zh) 2000-08-02
TW425397B (en) 2001-03-11
CN1220266A (zh) 1999-06-23
YU70494A (sh) 1997-03-07
AU7918894A (en) 1995-06-15
FI20011109A7 (fi) 2001-05-29
JPH07215977A (ja) 1995-08-15
RU2147304C1 (ru) 2000-04-10
NO944643D0 (no) 1994-12-02
CA2137203C (en) 2006-11-28
HUT71130A (en) 1995-11-28
HU9403468D0 (en) 1995-02-28
SG63570A1 (en) 1999-03-30
FI20000516A7 (fi) 2000-03-07
PT657458E (pt) 2002-02-28
KR950018010A (ko) 1995-07-22
NZ270048A (en) 1996-11-26
ATE204579T1 (de) 2001-09-15
JP3581731B2 (ja) 2004-10-27
CN1111247A (zh) 1995-11-08
NO308798B1 (no) 2000-10-30
FI945706A7 (fi) 1995-06-08
CN1050844C (zh) 2000-03-29
MY125587A (en) 2006-08-30
CO4340622A1 (es) 1996-07-30
YU49200B (sh) 2004-09-03
GR3037087T3 (en) 2002-01-31
IL111850A0 (en) 1995-03-15
IL111850A (en) 2002-11-10
UA44690C2 (uk) 2002-03-15
FI945706A0 (fi) 1994-12-02
DK0657458T3 (da) 2001-10-29
BR9404831A (pt) 1995-08-08
CZ301894A3 (en) 1995-06-14
DE69428025D1 (de) 2001-09-27
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
DE69428025T2 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
ES2162843T3 (es) Inhibidores de la proteina quinasa c.
ES2122764T3 (es) Inhibidor de la proteina quinasa c.
MX9707431A (es) Inhibidores de la proteina cinasa c.
PT758248E (pt) Formulacoes para o factor ix
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
ES2145978T3 (es) Intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n'.
MX9207264A (es) Compuestos de sulfonimidamida, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen
ES2175661T3 (es) Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ATE57526T1 (de) P-acylaminobenzamide.
ES2165020T3 (es) Monohidrato de famciclovir.
ECSP961938A (es) Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n, n-caso x - 10386
ECSP961937A (es) Inhibidor de proteina quinasa "c"
ECSP992875A (es) Inhibidores de la proteina /tirosina/ cinasa /de imidazopiracina sustituidas con heterociclo
ECSP982731A (es) Inhibidores de benzotiazol de la proteina tirosina cinasa
HN2000000112A (es) Compuestos de indazole y composiciones farmaceuticas para la inhibicion de proteina kinasa, y metodos para su uso.
ECSP972052A (es) Quinoxalinadionas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 657458

Country of ref document: ES